Cargando…

Patient Representation and Advocacy for Alzheimer Disease in Germany and Israel

This paper analyses self-declared aims and representation of dementia patient organizations and advocacy groups (POs) in relation to two recent upheavals: the critique of social stigmatization and biomedical research focusing on prediction. Based on twenty-six semi-structured interviews conducted in...

Descripción completa

Detalles Bibliográficos
Autores principales: Schicktanz, Silke, Rimon-Zarfaty, Nitzan, Raz, Aviad, Jongsma, Karin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6209015/
https://www.ncbi.nlm.nih.gov/pubmed/30066235
http://dx.doi.org/10.1007/s11673-018-9871-8
_version_ 1783366831174582272
author Schicktanz, Silke
Rimon-Zarfaty, Nitzan
Raz, Aviad
Jongsma, Karin
author_facet Schicktanz, Silke
Rimon-Zarfaty, Nitzan
Raz, Aviad
Jongsma, Karin
author_sort Schicktanz, Silke
collection PubMed
description This paper analyses self-declared aims and representation of dementia patient organizations and advocacy groups (POs) in relation to two recent upheavals: the critique of social stigmatization and biomedical research focusing on prediction. Based on twenty-six semi-structured interviews conducted in 2016–2017 with members, service recipients, and board representatives of POs in Germany and Israel, a comparative analysis was conducted, based on a grounded theory approach, to detect emerging topics within and across the POs and across national contexts. We identified a heterogeneous landscape, with the only Israeli PO focusing strongly on caretakers, whereas in Germany several POs claim to represent this patient collective. Shared aims of all POs were fighting social stigma, balancing the loss of patients’ individual autonomy, and the well-being of caretakers. By highlighting the emergence of new groups of dementia self-advocacy against the more traditional advocacy by others, this study highlights how advocacy and representation in the context of AD are embedded in the discursive context of stigmatization and revised disease conception. Future developments in early diagnosis and prediction of dementia, with more affected people likely to conduct dementia self-advocacy, might challenge existing representation structures even more.
format Online
Article
Text
id pubmed-6209015
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Springer Singapore
record_format MEDLINE/PubMed
spelling pubmed-62090152018-11-13 Patient Representation and Advocacy for Alzheimer Disease in Germany and Israel Schicktanz, Silke Rimon-Zarfaty, Nitzan Raz, Aviad Jongsma, Karin J Bioeth Inq Symposium: Collective Representation in Healthcare Policy This paper analyses self-declared aims and representation of dementia patient organizations and advocacy groups (POs) in relation to two recent upheavals: the critique of social stigmatization and biomedical research focusing on prediction. Based on twenty-six semi-structured interviews conducted in 2016–2017 with members, service recipients, and board representatives of POs in Germany and Israel, a comparative analysis was conducted, based on a grounded theory approach, to detect emerging topics within and across the POs and across national contexts. We identified a heterogeneous landscape, with the only Israeli PO focusing strongly on caretakers, whereas in Germany several POs claim to represent this patient collective. Shared aims of all POs were fighting social stigma, balancing the loss of patients’ individual autonomy, and the well-being of caretakers. By highlighting the emergence of new groups of dementia self-advocacy against the more traditional advocacy by others, this study highlights how advocacy and representation in the context of AD are embedded in the discursive context of stigmatization and revised disease conception. Future developments in early diagnosis and prediction of dementia, with more affected people likely to conduct dementia self-advocacy, might challenge existing representation structures even more. Springer Singapore 2018-07-31 2018 /pmc/articles/PMC6209015/ /pubmed/30066235 http://dx.doi.org/10.1007/s11673-018-9871-8 Text en © The Author(s) 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Symposium: Collective Representation in Healthcare Policy
Schicktanz, Silke
Rimon-Zarfaty, Nitzan
Raz, Aviad
Jongsma, Karin
Patient Representation and Advocacy for Alzheimer Disease in Germany and Israel
title Patient Representation and Advocacy for Alzheimer Disease in Germany and Israel
title_full Patient Representation and Advocacy for Alzheimer Disease in Germany and Israel
title_fullStr Patient Representation and Advocacy for Alzheimer Disease in Germany and Israel
title_full_unstemmed Patient Representation and Advocacy for Alzheimer Disease in Germany and Israel
title_short Patient Representation and Advocacy for Alzheimer Disease in Germany and Israel
title_sort patient representation and advocacy for alzheimer disease in germany and israel
topic Symposium: Collective Representation in Healthcare Policy
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6209015/
https://www.ncbi.nlm.nih.gov/pubmed/30066235
http://dx.doi.org/10.1007/s11673-018-9871-8
work_keys_str_mv AT schicktanzsilke patientrepresentationandadvocacyforalzheimerdiseaseingermanyandisrael
AT rimonzarfatynitzan patientrepresentationandadvocacyforalzheimerdiseaseingermanyandisrael
AT razaviad patientrepresentationandadvocacyforalzheimerdiseaseingermanyandisrael
AT jongsmakarin patientrepresentationandadvocacyforalzheimerdiseaseingermanyandisrael